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During the past decade, the treatment of patients with metastatic non–small-cell lung can-cer (NSCLC) has undergone a major paradigm shift. In the early 2000s, such patients 
were treated empirically with chemotherapy. Today, we know that NSCLC comprises multi-
ple clinically relevant molecular subsets defined by specific driver mutations. Such mutations 
result in constitutively active mutant signaling proteins and uncontrolled cellular proliferation. 
Remarkably, many of these mutant proteins are targetable with specific kinase inhibitors, and 
such treatment can be more effective than chemotherapy. The list of actionable targets is grow-
ing quickly, and currently includes at least epidermal growth factor receptor (EGFR) L858R 
substitutions and exon 19 deletion mutants,1 anaplastic lymphoma kinase (ALK) fusions,2 
ROS1 (c-ROS oncogene 1) fusions,3 MNNG-HOS transforming gene (MET) amplifications,4 
and BRAF V600E substitutions.5 EGFR mutants can be targeted with the EGFR kinase inhibi-
tors gefitinib or erlotinib, ALK/ROS1/MET aberrations can be treated with crizotinib, and 
BRAF (v-raf murine sarcoma viral oncogene homolog 1) V600E mutants with vemurafenib, 
respectively. In this issue of Journal of Thoracic Oncology, two case reports further extend 
this paradigm: the first case involves a new target, namely RET fusions, and the second case 
demonstrates mechanisms of sensitivity and resistance to another selective BRAF inhibitor in 
BRAF-mutant lung cancer.
Activating fusions involving the RET receptor tyrosine kinase were first reported 
in lung adenocarcinoma in 2012.6–9 RET (rearranged during transfection) was originally 
discovered as a proto-oncogene in 1985.10 Subsequently, mutations involving RET were 
found in papillary and medullary thyroid carcinomas, occurring in both hereditary and 
sporadic tumors.11,12 Some sporadic papillary thyroid cancers harbor RET fusions, with 
a higher prevalence found in patients with a history of radiation exposure, and in young 
adults and pediatric populations.13 Activating RET translocations have also been found in 
chronic myelomonocytic leukemia.14
In lung cancer, RET fusions are detected collectively in approximately 1% of 
NSCLCs.6,7,8,15 5′-fusion partners include NCOA4, CCDC6, and KIF5B. Clinical character-
istics associated with RET fusions include never-smoking status, adenocarcinoma histol-
ogy, and younger age at diagnosis. Importantly, such mutations are rarely, if ever, found in 
tumors that harbor mutations in other drivers, that is EGFR, KRAS, HER2, and ALK.8
Preclinical studies have suggested that lung cancers harboring RET fusions should be 
sensitive to inhibition with RET tyrosine-kinase inhibitors (TKIs). For example, a human 
lung adenocarcinoma cell line LC-2/ad with a CCDC6-RET fusion showed distinctive 
sensitivity to the RET inhibitor vandetanib but not gefitinib, among 39 NSCLC cell lines 
tested.16 Vandetanib inhibits both RET and EGFR, whereas gefitinib inhibits only EGFR. 
Other engineered cell line models show that RET fusions may also be sensitive to other 
kinase inhibitors with off-target RET activity, such as sunitinib, sorafenib, motesanib, and 
cabozantinib.17 In humans, one patient with RET-fusion–positive chronic myelomonocytic 
leukemia has had a documented cytological and clinical remission on sorafenib.14
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In this issue of Journal of Thoracic Oncology, Gautschi 
et al.18 report, to our knowledge, the first-known patient with 
RET-fusion–positive lung adenocarcinoma to respond to RET-
targeted therapy. This patient, who received vandetanib, had 
a tumor positive for a KIF5B-RET fusion and negative for 
other drivers, including mutations in EGFR, KRAS, BRAF, 
and HER2, fusions in ALK or ROS1, and MET amplification. 
Decrease in tumor size was observed after 1 week of vandetanib 
treatment; further imaging at 4 weeks of treatment confirmed 
the response. Treatment was well-tolerated by the patient.
A familiar challenge with targeted therapies is acquired 
resistance. Mechanisms of resistance have been well-charac-
terized in patients with EGFR- and ALK-mutant tumors.19 A 
common mechanism involves the development of second-site 
mutations. For RET, in vitro analyses have already identified 
mutations in RET codons 804 and 806 as mediators of van-
detanib resistance.20,21 In future studies, it will be important 
to establish whether this or other mechanisms are relevant to 
lung cancer patients treated with RET TKIs.
Although Gautschi et al.18 report findings from only a 
single patient, the identification of an RET-fusion–positive lung 
adenocarcinoma patient with response on vandetanib treatment 
suggests that RET fusions indeed represent another clinically 
actionable driver mutation in lung cancer. RET fusions should 
be screened for patients with lung adenocarcinoma, especially 
in tumors that lack known driver mutations. Important questions 
include: “What will be the response rate and overall survival 
in a cohort of patients prospectively treated with vandetanib? 
Is vandetanib the best RET TKI for treatment? Will there be 
enough patients to perform a randomized trial between chemo-
therapy and RET TKI to determine which is superior? How will 
acquired resistance be overcome? As these answers unfold, the 
speed with which observations are now translated from the lab-
oratory (RET fusions in lung cancer published February 2012) 
to the clinic (an RET-fusion–positive tumor responds to an RET 
TKI reported in February 2013) should provide inspiration and 
hope in the expanding era of molecularly targeted therapeutics.
Also, in this issue of Journal of Thoracic Oncology, 
Rudin et al. report the novel clinical course of a 63-year-old 
never-smoker with BRAFV600E-mutant lung adenocarcinoma, 
whose disease responded and then progressed on dabrafenib, 
a new selective BRAF inhibitor. BRAF mutations are found in 
approximately 2% of lung adenocarcinomas,22 but more than 
50% of melanomas. In the latter disease, dabrafenib has already 
been shown to be clinically superior to conventional chemother-
apy.23 Potential mechanisms of resistance to dabrafenib in mela-
noma include secondary mutations in NRAS, which encodes a 
GTPase, or MEK1, which encodes a serine-threonine kinase, 
both of which are downstream of BRAF in the RAF-RAS-
MEK-ERK signaling cascade.24 In the lung cancer case, analy-
sis of tumor tissue obtained after disease progression revealed a 
KRAS G12D mutation, which was not present in a pretreatment 
tumor biopsy. Like NRAS, KRAS encodes a GTPase in the same 
gene family. NRAS mutations are rare in lung adenocarcinoma, 
whereas KRAS mutations are relatively frequent.25 Given the 
similarities between NRAS and KRAS, the KRAS mutation prob-
ably mediated acquired resistance to dabrafenib in this patient.
Importantly, the novel finding in the patient treated with 
dabrafenib was possible because of the acquisition of serial tumor 
biopsies. Although no effective agents to date treat KRAS-mutant 
lung tumors effectively, this report highlights the importance of 
repeat mutational profiling to understand the mechanisms by 
which tumors inevitably evolve on targeted agents.
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